Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Trials Related to Lenalidomide
Related studies linked through entity extraction aliases.
Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)
- Status
- UNKNOWN
- Phase
- PHASE2
Investigation of the Enhancement of Response to Hepatitis B Vaccine by Lenalidomide in Plasma Cell Dyscrasias
- Status
- COMPLETED
- Phase
- PHASE2
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)
- Status
- TERMINATED
- Phase
- PHASE1
Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL
- Status
- COMPLETED
- Phase
- PHASE2
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
- Status
- COMPLETED
- Phase
- PHASE3
Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
- Status
- COMPLETED
- Phase
- PHASE3